CD19 and Miyoshi myopathy: At present, experience with bispecific CAR T cell therapy in MM is still very limited, and the published data of BCMA/CD38, BCMA/TACI and BCMA/CD19 targeted CAR T cell studies have not demonstrated any treatment associated neurotoxicity (51, 53, 54).